Why the study?
Atherosclerosis is a systemic disease where the risk of adverse cardiovascular events increases with the number of affected vascular beds, yet patients with peripheral arterial disease are often undertreated.
Risk modification and aggressive control of modifiable risk factors are essential for patients with polyvascular atherosclerotic disease, with revascularization reserved for symptomatic vascular beds.
Prioritize aggressive risk modification, limiting revascularization to symptomatic beds; reinforces consensus guidelines for polyvascular disease.
Atherosclerosis is a systemic disease affecting multiple arterial territories. Patients with clinical atherosclerotic disease in one vascular bed are likely to have asymptomatic or symptomatic atherosclerotic lesions in other vascular beds. Specifically, peripheral arterial disease (PAD) often coexists with coronary and carotid disease. With progression of atherosclerotic disease in one vascular bed, the risk of clinical manifestations in other territories increases and the incidence of adverse cardiovascular events increases substantially with the number of affected vascular beds. Classical risk factors are associated with the development of polyvascular atherosclerotic disease (PVD) in different territories; however, to a different extent. Risk modification represents basic treatment of patients with PVD. All modifiable risk factors should be aggressively controlled by lifestyle modification and medication. Particular attention should be directed to patients with PAD who are often undertreated in spite of the proven benefits of guideline-based approach. There is currently no proof that identification of asymptomatic atherosclerosis and PVD improves clinical outcomes in patients who are already in prevention programs. Revascularization should be performed only in symptomatic vascular beds, using the least aggressive method according to consensual decision of a multidisciplinary vascular team.
No takes yet. Share an insight, caveat, or question.
Poredoš et al. (2021) conducted a review in Polyvascular atherosclerotic disease. Aggressive risk modification is the basic treatment for polyvascular atherosclerotic disease, and revascularization should be performed only in symptomatic vascular beds.